Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients
Public ClinicalTrials.gov record NCT02445248. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Study identification
- NCT ID
- NCT02445248
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 115 participants
Conditions and interventions
Conditions
Interventions
- Lymphodepleting chemotherapy Drug
- Tisagenlecleucel Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 28, 2015
- Primary completion
- Dec 21, 2022
- Completion
- Dec 21, 2022
- Last update posted
- Apr 17, 2024
2015 – 2022
United States locations
- U.S. sites
- 12
- U.S. states
- 12
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCSF Medical Center . | San Francisco | California | 94143 | — |
| Emory University School of Medicine/Winship Cancer Institute SC CTL019 | Atlanta | Georgia | 30322 | — |
| University of Chicago Medical Center Hematology and Oncology SC - CTL019B2207J | Chicago | Illinois | 60637 | — |
| University of Kansas Cancer Center SC - CTL019C2201 | Westwood | Kansas | 66205 | — |
| Sidney Kimmel Comprehensive Cancer Center SC-2 | Baltimore | Maryland | 21287-0013 | — |
| Uni of Michigan Health System SC CTL019 | Ann Arbor | Michigan | 48109 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Weill Cornell Medical College | New York | New York | 10065 | — |
| The Ohio State University James Cancer Hospital & | Columbus | Ohio | 43210 | — |
| Oregon Health Sciences University Oregon Health & Sci Uni | Portland | Oregon | 97239 | — |
| University of Pennsylvania Perelman School of Medicine | Philadelphia | Pennsylvania | 19104 | — |
| MD Anderson Cancer Center SC | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02445248, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 17, 2024 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02445248 live on ClinicalTrials.gov.